New real-world evidence on the MSDA Test published in The Multiple Sclerosis Journal – ET&C. Read the press release. 

Contact Us

CCTAVE EVENTS

May 28 - 31, 2025
Phoenix, AZ

Octave at the CMSC 2025 Annual Meeting

Join Our CMSC Program

Dinner & Dialogue: Insights From a Clinician

Unlock the Power of Biomarkers in MS Care

Presenter: Ajo Joy, MD

Date: Wednesday, May 28 2025
Time: 6:30 PM
Location: Chico Malo (50 W Jefferson St)

Register

Supporter Showcase

Clinical Conversations in MS:
How Fluid Biomarkers are Reshaping When to Initiate, Switch, or Discontinue DMTs

Moderator: Gabriel Pardo, MD
Panelists: Jacqueline Nicholas, MD, MPH & Mitzi Joi Williams, MD

Date: Friday, May 30 2025
Time: 12:30 – 1:00 PM
Location: Exhibit Hall (North Hall C-E), Showcase 1

No preregistration required, available to all registered CMSC attendees

Explore Octave's Posters

Thursday, May 29 | 5:00 - 7:00 PM

NIB01 – Comparison of Natalizumab, Ocrelizumab, and Diroximel Fumarate in RRMS Patients to Characterize Proteomic, Radiomic, and Clinical Trajectories: Interim Study Results

NIB07 – Real-World Utilization of a Novel Multi-Analyte Blood Based Biomarker Panel, the Octave Multiple Sclerosis Disease Activity Test in Clinical Practice in the United States

CSR21 – Measuring Outcomes and Value: An Integrated, Novel Solution for Generating Insights in MS (MOVING-MS) Study: Case Trajectories Supported By Multi-Modal Insights

MOC16 – Using Blood-Based Biomarkers to Monitor Discontinuation of Therapy in Individuals with Relapsing Multiple Sclerosis: A Case Series

DMT34 – Two-Year Findings on the Safety and Efficacy of Cladribine Tablets after Treatment with Natalizumab (CLADRINA Trial)

Booth #401

Visit us to learn how the Octave MSDA Test is transforming MS care with actionable insights.

Connect with our team and discover how fluid biomarkers can elevate clinical decision-making.

Schedule time with us

© 2025 Octave Bioscience, Inc | 1440 O’Brien Drive, Suite B, Menlo Park, CA 94025 

Connect with us